India has opposed the global trend and is showing continued improvement in the content of the Covid-19 explosion, senior officials said on Tuesday, but warned that trends in other countries are also strongly reminiscent of how the situation can quickly control even if one peak is contained.
Speaking at the government’s routine briefing on the situation of Covid-19, Union Secretary-General Rajesh Bhushan and member of Niti Aayog (health) VK Paul also listed the legal work across the country for the logistics and training that will be delivered vaccines to hundreds of millions of people by next summer.
“Active cases have declined from more than 10 lakhs in mid-September to less than four lakhs today … India’s cumulative death rate has also fallen to 6.37%, and if you consider the last week, it is 3%,” he said. Bhushan, before talking about the continued growth of infections and deaths in other countries.
Paul described the contrast between India and the world as a warning as well as a source of satisfaction. “It’s reminiscent of the nature of the virus, because even we could get a second wave of infections and deaths, because that’s how this virus behaves. Things can turn drastically even after it stabilizes. The key lesson is that you don’t take things as intended. , “he said.
On the other hand, he added, “it is reassuring that we are saving lives. Our situation is now similar to July. People are now saying that the R-nine has been reduced below 1 and the explosion is declining.” Paul stressed the need to be cautious, saying, “Remember, we have a large population of people vulnerable.”
On Tuesday, 26,249 new infections were reported across the country, bringing the total number of confirmed cases in the country to 9,932,841, according to HT’s Covid-19 panel. Meanwhile, 385 more patients have lost their lives due to the disease in the past 24 hours, bringing the total number of deaths in the country to 144,149.
Niti Aayog’s official highlighted the case of the national capital, congratulating the Delhi government and the relevant departments for controlling the explosion. “But even as many regions show improvement, some are still worrying, like Uttarakhand, Nagaland and Himachal Pradesh. We are in contact with officials there,” Paul said.
According to Bhushan, preparations are being made to prepare local officials to receive and administer vaccines, a process that is likely to cover close to 300 million people by the middle of next year. “We will use 29,000 cold chain points, 240 entry-level refrigerators, 70-entry freezers, 45,000 ice freezers, 41,000 deep freezers and 300 solar refrigerators. All of these have already reached states and more equipment is being sent,” the health secretary added.
The supplies were among three broad focuses of detailed guidelines sent to the states. These mostly dealt with assignment of responsibilities (Bhushan said 23 ministries and departments of Center and states were given their roles), training and equipping people who will be engaged in logistics and management of shootings, and on how to control and respond to any adverse reactions , which people might have.
“Instructions (were) issued on mild, severe and severe AEFI (adverse effect after immunization). States will identify one AEFI management center in each block that could be fixed health facilities. Each AEFI management center will be mapped with all session sites (vaccines). centers) to ensure that people can be led to these without delay, ”Bhushan said.
These preparations are made while at least three vaccine candidates are evaluated for acute approval. Paul said there has been good progress in the vaccine pipeline, and highlighted a Gennova candidate that is based on the same mRNA platform as the doses developed by Pfizer and Moderna and was released for clinical trials last week. “Unlike Pfizer and Modern, this vaccine will require normal cold chain temperatures,” Paul said.
Certainly, this vaccine candidate has just been released for Phase 1/2 trials. After that, it will be subject to approvals and enter Phase 3 trials.
“We now have six vaccines undergoing human testing in India,” he said, adding that the approval and evaluation process is being conducted in an independent and objective manner. “This process is being carried out by independent experts and people need to be reassured that whatever vaccine is approved, it will be based on established scientific and global parameters,” the officials said.
The Comptroller General for Drugs is assessing urgent authorization requests from Pfizer, Serum Institute of India and Bharat Biotech. Of these, Pfizer has been approved in several countries after performing phase III tests and finding an efficiency close to 95%.
Serum Institute requested approval of the vaccine developed by Oxford University and AstraZeneca, which showed an efficacy of 62% -90%, according to a provisional analysis. Bharat Biotech is currently conducting phase III testing. Both of these companies were asked by the departmental committee of the DCGI (SEC) to submit more data related to their tests so that their applications could be evaluated.